KROS Quote, Financials, Valuation and Earnings

Merck & has a net margin of 70.27% compared to Keros Therapeutics's net margin of 32.71%. Keros Therapeutics's return on equity of 0.78% beat Merck &'s return on equity of 39.02%.

Keros Therapeutics has a consensus price target of $30.60, signalling upside risk potential of 117.18%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 28.31%. Given that Keros Therapeutics has higher upside potential than Merck &, analysts believe Keros Therapeutics is more attractive than Merck &.

Keros Therapeutics has a beta of 1.306, which suggesting that the stock is 30.579% more volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.98% to investors and pays a quarterly dividend of $0.81 per share. Keros Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Keros Therapeutics quarterly revenues are $211.2M, which are smaller than Merck & quarterly revenues of $15.5B. Keros Therapeutics's net income of $148.5M is lower than Merck &'s net income of $5.1B. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.54x versus 3.15x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 70.27% compared to Keros Therapeutics's net margin of 26.7%. Keros Therapeutics's return on equity of 0.78% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Keros Therapeutics has a consensus price target of $30.60, signalling upside risk potential of 117.18%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 40.5%. Given that Keros Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Keros Therapeutics is more attractive than Regeneron Pharmaceuticals.

Keros Therapeutics has a beta of 1.306, which suggesting that the stock is 30.579% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Keros Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $211.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Keros Therapeutics's net income of $148.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.54x versus 4.19x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 70.27% compared to Keros Therapeutics's net margin of --. Keros Therapeutics's return on equity of 0.78% beat Viking Therapeutics's return on equity of --.

Keros Therapeutics has a consensus price target of $30.60, signalling upside risk potential of 117.18%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 224.34%. Given that Viking Therapeutics has higher upside potential than Keros Therapeutics, analysts believe Viking Therapeutics is more attractive than Keros Therapeutics.

Keros Therapeutics has a beta of 1.306, which suggesting that the stock is 30.579% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.236%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $211.2M, which are larger than Viking Therapeutics quarterly revenues of --. Keros Therapeutics's net income of $148.5M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.54x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of 70.27% compared to Keros Therapeutics's net margin of -82.56%. Keros Therapeutics's return on equity of 0.78% beat Verastem's return on equity of -120.71%.

Keros Therapeutics has a consensus price target of $30.60, signalling upside risk potential of 117.18%. On the other hand Verastem has an analysts' consensus of $15.75 which suggests that it could grow by 145.33%. Given that Verastem has higher upside potential than Keros Therapeutics, analysts believe Verastem is more attractive than Keros Therapeutics.

Keros Therapeutics has a beta of 1.306, which suggesting that the stock is 30.579% more volatile than S&P 500. In comparison Verastem has a beta of 0.850, suggesting its less volatile than the S&P 500 by 15.045%.

Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

Keros Therapeutics quarterly revenues are $211.2M, which are larger than Verastem quarterly revenues of $10M. Keros Therapeutics's net income of $148.5M is higher than Verastem's net income of -$52.1M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.54x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.